E Fund Management’s Arcutis Biotherapeutics ARQT Stock Holding History

E Fund Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Sell	11,390 -11,617	-50%	-$271K	0.01%	380
2026 Q1	$542K	Buy	+23,007	New	+$587K	0.02%	278
2025 Q2	$241K	Buy	17,184 +2,197	+15%	+$30.8K	0.01%	340
2025 Q1	$234K	Buy	14,987 +108	+0.7%	+$1.52K	0.01%	347
2024 Q4	$207K	Sell	14,879 -2,906	-16%	-$31.8K	0.01%	358
2024 Q3	$165K	Buy	17,785 +2,026	+13%	+$20K	0.01%	337
2024 Q2	$147K	Sell	15,759 -23,107	-59%	-$209K	0.01%	302
2024 Q1	$385K	Buy	+38,866	New	+$290K	0.02%	231
2023 Q4	–	Sell	-21,535	Closed	-$114K	–	310
2023 Q3	$114K	Sell	21,535 -5,342	-20%	-$45.4K	0.01%	278
2023 Q2	$256K	Buy	26,877 +9,578	+55%	+$106K	0.02%	238
2023 Q1	$190K	Buy	17,299 +1,419	+9%	+$20.5K	0.01%	306
2022 Q4	$235K	Buy	15,880 +3,933	+33%	+$68.7K	0.02%	272
2022 Q3	$228K	Buy	+11,947	New	+$271K	0.02%	279

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

E Fund Management's ARQT Position: Q2 2026 in Review

E Fund Management reduced its Arcutis Biotherapeutics (ARQT) stake by 50% in Q2 2026, selling an estimated $271K and leaving 11,390 shares worth $299K. The position accounts for 0.01% of the portfolio, ranked #380.

E Fund Management first reported a position in ARQT in Q3 2022 and has held it in 13 quarters since. The position peaked at $542K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

E Fund Management held 11,390 shares of Arcutis Biotherapeutics worth $299K as of Q2 2026.
E Fund Management sold 11,617 Arcutis Biotherapeutics shares in Q2 2026, an estimated $271K.
Arcutis Biotherapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #380 holding.
E Fund Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 13 quarters since.
E Fund Management's Arcutis Biotherapeutics position peaked at $542K in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.